Reduction of stroke events with pravastatin: The Prospective Pravastin Pooling (PPP) Project

Circulation

Volumn 103, Issue 3, 2001, Pages 387-392

  Byington, Robert P ^a   Davis, Barry R ^b   Plehn, Jonathan F ^c   White, Harvey D ^d   Baker, Jennifer ^e   Cobbe, Stuart M ^f   Shepherd, James ^f  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c ST FRANCIS HOSPITAL   (United States)

^d GREEN LANE HOSPITAL   (New Zealand)

^e THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Lipids; Prevention; Stroke; Trials

Indexed keywords

LIPID; PLACEBO; PRAVASTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 0035936503     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.3.387     Document Type: Article

References (28)

1. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events in the Pravastatin Atherosclerosis Intervention Program
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Prevention of coronary disease with pravastatin in men with hypercholesterolemia
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Cholesterol reduction and the risk of stroke in men: A meta-analysis of randomized, controlled trials
7. An overview of trials of cholesterol lowering and risk of stroke
8. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: A combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol And Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)
9. Pravastatin reduces mortality in patients with a broad range of lipid levels with or without prior coronary heart disease: The Prospective Pravastatin Pooling Project
10. The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project
11. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) Study
12. Impact of pravastatin therapy on the risk of stroke: Results from the LIPID Study
13. Cholesterol, diastolic blood pressure and stroke: 13,000 Strokes in 450,000 people in 45 prospective cohorts
14. Reductase inhibitor mono-therapy and stroke prevention
15. Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
16. Cholesterol lowering with statin drugs, risk of stroke, and total mortality
17. HMG-CoA reductase inhibitor therapy and stroke reduction: An analysis of clinical trial data
18. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Group
19. Pravastatin, lipids, and atherosclerosis in the Carotid Arteries (PLAC-II)
20. Kuopio Prevention Study (KAPS): A population-based primary prevention trial of the effects of LDL lowering on atherosclerotic progression in carotid and femoral arteries
21. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy
22. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
23. Lipids and stroke: Neglect of a useful preventive measure?
24. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial